Immunotherapy: Stages of Care and Treatment Options for Cancer

Cancer care has evolved significantly over recent decades, and immunotherapy now stands as one of the most studied and discussed approaches in oncology. From the initial consultation to ongoing monitoring, the journey through immunotherapy involves several structured stages, each with its own purpose and process. This article outlines those stages and explains what patients can generally expect along the way.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

Initial Assessment and Eligibility Screening

Before any immunotherapy begins, a medical team evaluates whether a patient is a suitable candidate. This involves reviewing the type and stage of cancer, the patient’s overall health, prior treatments, and biomarker testing — such as checking for PD-L1 expression or specific genetic mutations. Not all cancer types respond equally to immunotherapy, so this screening phase is critical. Blood tests, imaging scans, and biopsy analysis are commonly used tools during this stage to gather the information needed for a personalized treatment approach.

Treatment Planning and Informed Consent

Once eligibility is confirmed, the oncology team develops a tailored treatment plan. This plan outlines the specific type of immunotherapy recommended — such as checkpoint inhibitors, CAR-T cell therapy, or cancer vaccines — along with the dosing schedule and administration method. Informed consent is a vital part of this stage. Patients receive detailed information about the potential benefits, known side effects, and alternatives. This dialogue ensures that the patient understands what lies ahead and is an active participant in their own care decisions.

Induction and Activation Phase of Therapy

The induction or activation phase is when treatment formally begins. During this period, the immune system is stimulated or modified to target cancer cells. For checkpoint inhibitors, this typically involves intravenous infusions administered over several weeks. For cellular therapies like CAR-T, the patient’s own immune cells are collected, genetically modified in a laboratory, and then reinfused. This phase can be intensive, and patients are closely monitored for immune-related adverse events, which can range from mild fatigue to more serious inflammatory responses depending on the individual and the therapy type.

Maintenance, Dosing Adjustments, and Scheduling

Following the initial treatment phase, many patients enter a maintenance stage where therapy continues at adjusted intervals. Dosing may be modified based on how well the patient is tolerating the treatment and how the cancer is responding. Regular imaging and lab work are used to track effectiveness. Scheduling is often flexible but structured, with treatment cycles typically ranging from two to six weeks depending on the protocol. This phase can last months or even years in some cases, requiring ongoing communication between the patient and their care team to manage any emerging side effects or changes in health status.

Understanding Side Effects and Immune Responses

One of the defining characteristics of immunotherapy is that its side effects differ from those of conventional treatments. Because the immune system is being activated, patients may experience inflammation in various organs — a condition known as immune-related adverse events (irAEs). Common examples include skin rashes, colitis, hepatitis, or thyroid dysfunction. Early identification and management of these effects is a core component of immunotherapy care. In many cases, corticosteroids or other immunosuppressive medications are used to bring these reactions under control without stopping the therapy entirely.

Monitoring Progress and Long-Term Follow-Up

Assessing how well immunotherapy is working can sometimes be complex. Tumors may initially appear larger on scans due to immune cell infiltration — a phenomenon sometimes called pseudoprogression — before they begin to shrink. Oncologists use a combination of imaging, blood markers, and clinical evaluation to determine true response. Long-term follow-up remains essential even after treatment concludes, as some patients experience delayed responses or late-onset side effects. Regular check-ins help ensure that any recurrence or new developments are addressed as early as possible.

Immunotherapy represents a meaningful shift in how cancer care is delivered. Its staged approach — from eligibility screening through long-term monitoring — reflects the complexity of harnessing the immune system for therapeutic purposes. For patients navigating this path, understanding each phase can reduce uncertainty and support more informed conversations with their healthcare team.